Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
117
resultados
Última actualización
19/08/2026 [08:36:00]
Resumen de: CN122582271A
本发明公开一种基于细菌的肿瘤原位疫苗，包括灭活细菌和腺苷脱氨酶，所述灭活细菌为大肠杆菌(Escherichia coli) Nissle 1917或减毒鼠伤寒沙门氏菌(VNP 20009)中的任意一种或两种。本发明的肿瘤原位疫苗对宿主脏器无明显毒副作用，具有良好的安全性，生产制备工艺简单、成本低；可通过瘤内注射方式刺激机体先天性和适应性免疫系统，增强抗肿瘤免疫，抑制肿瘤细胞生长，有效预防肿瘤的发生发展和复发转移。
Resumen de: CN115715198A
The present invention relates to a DNA vaccine comprising a Salmonella typhi Ty21a strain, the Salmonella typhi Ty21a strain comprising a DNA molecule, the DNA molecule comprising an eukaryotic expression cassette encoding at least a COVID-19 coronavirus (SARS-CoV-2) spike (S) protein or a portion thereof. In particular, the invention relates to the application of the DNA vaccine to prevention and/or treatment of the coronavirus disease COVID-19 or SARS-CoV-2 infection.
Resumen de: CN122563840A
本发明公开了一种肿瘤靶向定植且肠道可条件性清除的工程菌及其应用。该工程菌首次整合了“肿瘤专性定植回路”与“大肠杆菌素条件性敏感回路”：通过营养缺陷型突变（ΔaroA）与缺氧依赖性增殖回路（P hypox ‑ftsZ）的双重锁定，实现严格的肿瘤微环境专性定植；通过外源大肠杆菌素受体基因与时间延迟免疫蛋白回路的协同，实现在肠道穿越窗口期（约0‑4小时）内对大肠杆菌素耐受、穿越完成后恢复敏感的条件性清除能力。本发明工程菌解决了口服活菌制剂“既要高效穿越肠屏障、又要彻底清除肠道残留”的核心矛盾，为肿瘤细菌疗法提供了安全、可控的活体底盘，可广泛用作定植菌或效应菌应用于各类级联放大肿瘤免疫治疗系统。
Resumen de: US20260232581A1
0000 The present disclosure provides pharmaceutical compositions for use in delivering therapeutics, such as vaccines or biologic material, to the nasal cavity or the deep lungs. In particular, the pharmaceutical compositions may preferentially deposit on the lower or middle turbinate region and the nasopharynx region of the nasal cavity. In other aspects the pharmaceutical compositions may be used to generate powders that penetrate the deep lungs. Also, provided herein are methods of preferential delivery to these regions.
Resumen de: WO2026170052A1
The present invention provides for enrichment of animal foodstuffs using endolysin polypeptides or fragments thereof, which possess antimicrobial activity (e.g., against gram-negative bacteria, such as Salmonella enterica). The invention also provides for nucleic acid molecules encoding the endolysin, and methods of their production. Also provided are compositions comprising the endolysins, or comprising any of the means for producing the endolysin (e.g., a host cell, lysate, or dried product, etc.) that has antimicrobial activity, for the use of said compositions in a method of reducing the population of gram-negative bacteria in a foodstuff, or preventing or treating a disease or disorder in an animal.
Resumen de: EP4790026A1
0001 Apparatus for treating various fluids, such as wine, must, water, oil, sauce, fruit juice, and others, to prevent contamination or the development and spread of diseases such as salmonella and legionella. The apparatus allows to avoid excessive proliferation of colonies of bacteria and yeasts which, if present in excessive quantities, can cause mould and pathogens in general. The apparatus comprises a container body containing a reticular cathode and anode that allow the liquid to pass through and are powered by an electrical connector that receives electrical current from a power supply controlled by an electronic control unit. The container body is configured to be immersed in the liquid to be treated, allowing the liquid to flow through the cathode and anode, which generate a pulsed electric field. The electrical signal has a frequency of about 300 Hz, an amplitude of 100V and pulses of few milliseconds. To increase the efficiency of the treatment, the signal changes polarity every 90 seconds.
Resumen de: WO2022036159A2
Provided are attenuated immunostimulatory bacteria with genomes that are modified to, for example, reduce toxicity and improve the anti-tumor activity, such as by increasing accumulation in the tumor microenvironment, particularly in tumor- resident myeloid cells, improving resistance to complement inactivation, reducing immune cell death, promoting adaptive immunity, and enhancing T-cell function. Also provided are immunostimulatory bacteria for use as vaccines, and for delivery of mRNA. The increase in colonization of phagocytic cells improves the delivery of encoded therapeutic products to the tumor microenvironment and to tumors and permits, among other routes, systemic administration of the immunostimulatory bacteria. The increase in colonization of phagocytic cells also provides for use of immunostimulatory bacteria for direct tissue administration for use as vaccines.
Resumen de: CN122521544A
本发明公开了一种可分泌微菌素MccY的减毒鸡白痢沙门菌（pMccY‑asd），其制备方法及应用，归属于禽沙门菌病的防治领域。本发明提供的鸡白痢减毒沙门菌毒力显著降低，能有效清除强力菌株感染，并可应用平板凝集试验对免疫接种鸡和自然感染鸡予以区分。通过宿主载体平衡致死系统构建pMccY‑asd质粒，可以使菌株在不依赖抗生素筛选的情况下锁定质粒，并且持续高效地分泌表达MccY，对野生型鸡白痢沙门菌及不同血清型沙门菌有较好的抑菌作用。
Resumen de: CN122520725A
本发明公开了一种沙门菌属特异性抗原片段、基因、试剂盒及其在检测鸡血清中沙门菌抗体中的应用。所述沙门菌属特异性抗原PagN片段的氨基酸序列如SEQ ID NO.1所示。本发明首次公开了沙门菌属特异性抗原PagN片段在沙门菌鸡群感染的血清学诊断价值，并将其作为间接ELISA的包被抗原，建立了沙门菌抗体间接ELISA检测方法。沙门菌外膜蛋白PagN片段能够特异性识别沙门菌属抗体，能绕过血清型差异造成的检测障碍，迅速锁定沙门菌属感染，适用于临床中需要快速初筛的场景。本发明能够用于鸡群中沙门菌属抗体的检测，为沙门菌的流行病学调查以及沙门菌感染的精准防控提供了有力的技术支持。
Resumen de: US2017000831A1
0001 The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Escherichia coli strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.
Resumen de: US20260227396A1
0000 A method for identifying a multi-parameter phenotype of microbiota. The method includes (i) providing a sample including microbiota, (ii) labeling the microbiota with multiple labels, each of which binds a phenotypic parameter of the microbiota, (iii) detecting an intensity of the labelled phenotypic parameters of single cells of the microbiota by flow cytometry, and (iv) segmenting the single cells into bins based on the intensities of detected phenotypic parameters, wherein the distribution of single cells in bins represents a multi-parameter phenotype of said microbiota. Also described is a system for identifying a multi-parameter phenotype of intestinal microbiota, a kit for identifying a multi-parameter phenotype of intestinal microbiota and methods for diagnosing a medical condition associated with microbiota, for example an inflammatory condition, such as an inflammatory bowel disease, in a subject.
Resumen de: US20260227395A1
0000 The disclosure provides a three-dimensional (3-D) macroporous melamine foam membrane comprising an amine reactive group. The membrane foam can be used to perform ELISA assays for the detection of an analyte. Diffusion of the analyte through the different membrane layers is fast and homogeneous in all directions and suitable for detection of large volume of samples in low concentration of targets and multiple targets simultaneously in one integrated system with minimal interference from targets.
Resumen de: US20260226485A1
0000 Aspects of the present disclosure relate to modified yeast cells capable of producing increased quantities of squalene as compared to unmodified yeast cells and methods of using the same.
Resumen de: WO2026165108A1
The present inventive concept provides methods using non-toxic compositions that include components selected from ethanol, polymers, polar aprotic solvents, water, organic acids, phospholipids, polyols, polysaccharides, phenols, plant extracts, organic salts, peroxide, and peptide antibiotics designed as hygienic agents for the poultry and livestock industries. The compositions and methods provide a safer alternative to use of traditional formaldehyde (e.g., aldehyde-based) compositions by incorporating non-toxic preservation and antimicrobial agents to enhance biosecurity and sanitation in the livestock environments, and in particular, poultry production environments. The methods provided herein also control the growth of pathogenic bacteria such as Salmonella, Campylobacter, Streptococcus, Staphylococcus, E. coli, Clostridia, and Bacillus. Moreover, the methods and compositions provide safer working conditions by eliminating workers' exposure to carcinogenic substances.
Resumen de: WO2026165563A1
Disclosed are methods for inoculating embryonated avian eggs for conferring protective immune responses against diseases caused by a diversity of bacterial, viral and parasite pathogens. According to certain aspects methods are disclosed that involve administering, in ovo, a safe inoculating dose of a Protective Immunity Enhanced Salmonella Vaccine (PIESV) strain, or derivative thereof, and optionally co-administering a safe inoculating dose of a live self-destructing attenuated adjuvant Salmonella strain (SDAAS), or derivative thereof.
Resumen de: WO2026165105A1
The present inventive concept provides non-toxic compositions that include components selected from ethanol, polymers, polar aprotic solvents, water, organic acids, phospholipids, polyols, polysaccharides, phenols, plant extracts, organic salts, peroxide, and antibiotics. The compositions are designed as an enhancement or additive to animal feed additives, animal feedstuff, animal feed, or animal hydration sources. The compositions provide a safer alternative to traditional formaldehyde (e.g., aldehyde-based) compositions by incorporating preservative and antimicrobial agents into animal feed products. The compositions provided herein render animal feed highly resistant to recontamination by pathogenic bacteria such as Salmonella, Campylobacter, Streptococcus, Staphylococcus, E. coli, Clostridia, and Bacillus. Moreover, the compositions provide safer working conditions by eliminating workers' exposure to carcinogenic substances.
Resumen de: CN122502457A
本发明公开了一种具有免疫增强功能的蛋白、其编码基因及应用。本申请所述具有免疫增强功能的蛋白的氨基酸序列如SEQ ID NO.1所示。该蛋白取自鼠伤寒沙门菌鞭毛蛋白FliC的C端部分序列，不仅保留了鞭毛蛋白固有的免疫增强活性，还显著降低了其免疫原性；将其应用于含铝佐剂的猪圆环病毒2型亚单位疫苗时，可有效增强该疫苗的免疫原性，诱导体液和细胞免疫应答，并显著促进抗原特异性的Th1和Th2型免疫应答，对完善现有含铝佐剂亚单位疫苗的配方、提升疫苗免疫效果具有重要意义。
Resumen de: CN122502436A
本发明适用于微生物技术领域，提供了一种基于噬菌体展示技术筛选的沙门菌模拟抗原表位肽及应用，其中，该沙门菌模拟抗原表位肽能够与抗沙门菌的多克隆抗体特异性结合，其包括如序列表SEQ ID NO:1‑4所示的一种或多种氨基酸序列。本发明筛选的沙门菌模拟抗原表位肽能特异性结合抗沙门菌的多克隆抗体，显著诱导机体体液免疫和细胞免疫应答，并对多种沙门菌血清型及产肠毒素大肠杆菌可以产生交叉保护，攻毒存活率高，安全性好。本发明为由革兰氏阴性病原体引起的疾病的预防和治疗提供了一种全新的有效疫苗。
Resumen de: US20260218209A1
The present invention is directed to a method for increasing conjugation efficiency of a basic conjugative element by inserting into the leading region sequence of the conjugative element an anti-defense nucleotide sequence encoding at least one anti-defense gene.
Resumen de: US20260219269A1
0000 A method and kit for for determining of an effective concentration of an antimicrobial agent for inhibiting bacterial growth are provided. The method and kit involve the use of a first and second multiwell receptacle. A fluid sample containing or suspected to contain one or more microbial organisms is dispensed into the wells of the first multiwell receptacle containing a range of dilutions of an antimicrobial agent, growth medium and a bacteriophage to form assay mixtures in the wells. The assay mixtures are then transferred to the corresponding wells of the second multiwell receptacle for detection.
Resumen de: WO2025064651A1
A sensor-enabled pathogen identification, differentiation, and quantification system that integrates into supply chains in an end-to-end fashion and is built on a multi-source, multi-sectoral data environment. The system uses portable sensing platforms that are easily integrated at multiple points along a supply chain and which integrate sample analysis and data processing such that all necessary work can be performed on-site and/or via wireless data transfer.
Resumen de: US20260207687A1
0000 A composition of bacteriophages comprising at least one phage selected from TTS1, TTS2, TTS3, TTS4, TTS5, and TTS6, wherein the phages are optionally encapsulated; and a method for preventing or treating an infection caused by Salmonella Gallinarum by administering to a subject a therapeutically effective amount of the composition.
Resumen de: WO2025003119A1
The invention relates to a method for detecting and confirming at least one Shiga toxin-producing Escherichia Coli (STEC) which may be present in a sample comprising enterobacteria, comprising the following steps: - performing lysis of the sample, enabling lysis of the STECs in order to obtain a solution comprising the nucleic acids thereof; - bringing the solution of nucleic acids into contact with primers, making it possible to amplify at least the stx1 and/or stx2 gene or gene fragment; - if at least one of the stx1 and/or stx2 genes or gene fragments is amplified, part of the sample is deposited on an agar reaction medium comprising ■ at least one toxin inducer, ■ at least one agglutinating conjugate formed by at least one binding partner specific to the STX1 protein and/or at least one binding partner specific to the STX2 protein, which binding partner(s) is (are) coupled to a nanoparticle; - detecting and confirming the presence of at least one STEC by the appearance of a halo on the agar around the STEC.
Resumen de: CN122427295A
本发明涉及生物技术、动物防疫领域，具体涉及一种α和ε型产气荚膜梭菌的融合蛋白、亚单位疫苗组合物及其应用。本发明通过将产气荚膜梭菌ε蛋白片段、产气荚膜梭菌α蛋白片段、鼠伤寒沙门氏菌鞭毛蛋白片段利用柔性连接肽顺序连接，构建得到了一种无毒力、安全性高、能够有效刺激机体产生抗体的融合蛋白，其氨基酸序列如SEQ ID NO:13所示。该融合蛋白经大量分泌表达后，蛋白含量不低于575μg/mL，蛋白纯度不低于87%。本发明进一步以融合蛋白为抗原，制备得到了一种能够同时预防产气荚膜梭菌α毒素和ε毒素引起的疾病的亚单位疫苗组合物，其制备方法简单、生产成本低，免疫效果好，具有高效的中和与攻毒保护能力，持久免疫应答能力，同时质量稳定、安全性高。
Nº publicación: WO2026150325A1 16/07/2026
Solicitante:
YEDA RES & DEV [IL]
BACCINE LTD [IL]
YEDA RESEARCH AND DEVELOPMENT CO. LTD.
BACCINE LTD.
Resumen de: WO2026150325A1
A pharmaceutical combination and uses thereof, wherein the pharmaceutical combination comprises a tumor-homing bacteria and a host-transient bacterial adjuvant comprising a supplementary dose of an immunostimulant.
BOPI
Sede Electrónica
